New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies

In metastatic renal cell carcinoma (mRCC) the PD-1 immune-checkpoint inhibitor (ICI) Nivolumab became a standard second line treatment option in 2015 based on a significant improvement of overall survival compared to Everolimus. Current pivotal phase 3 studies showed that PD-1 ICI-based combinations...

Descripción completa

Detalles Bibliográficos
Autores principales: Grimm, Marc-Oliver, Leucht, Katharina, Grünwald, Viktor, Foller, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074019/
https://www.ncbi.nlm.nih.gov/pubmed/32092974
http://dx.doi.org/10.3390/jcm9020565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074019/
https://www.ncbi.nlm.nih.gov/pubmed/32092974
http://dx.doi.org/10.3390/jcm9020565

Ejemplares similares